Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Polish Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hankey, G. J.
Right arrow Articles by Eikelboom, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hankey, G. J.
Right arrow Articles by Eikelboom, J. W.
Related Collections
Right arrow All Clinical trials
Right arrow All Cerebrovascular disease/Stroke
Right arrow Infarction
NEUROLOGY 2005;64:1117-1121
© 2005 American Academy of Neurology
Views & Reviews

Adding aspirin to clopidogrel after TIA and ischemic stroke

Benefits do not match risks

Graeme J. Hankey, MD, FRCP, FRACP and John W. Eikelboom, MBBS, MSc, FRACP, FRCPA

From the Stroke Unit, Department of Neurology (Dr. Hankey), Royal Perth Hospital and School of Medicine and Pharmacology (Dr. Hankey), University of Western Australia, Perth; and Thrombosis Service (Dr. Eikelboom), McMaster University, Hamilton Health Sciences-General Division, Hamilton, Ontario, Canada.

Address correspondence and reprints requests to Dr. Graeme J. Hankey, Stroke Unit, Department of Neurology, Royal Perth Hospital, 197 Wellington Street, Perth, Australia 6001; e-mail: gjhankey{at}cyllene.uwa.edu.au

Antiplatelet therapy is effective for reducing the risk of recurrent stroke and other serious vascular events in patients with recent TIA and ischemic stroke. Effective antiplatelet agents include aspirin, ticlopidine, clopidogrel, dipyridamole, and the combination of aspirin and dipyridamole. The combination of aspirin and clopidogrel is more effective than aspirin in patients with acute coronary syndrome but is more hazardous than clopidogrel alone in patients with recent TIA and ischemic stroke. Further trials are needed to determine whether the combination of aspirin and clopidogrel may have a role immediately after TIA and ischemic stroke in patients with symptomatic large artery atherothromboembolism and continued for approximately 3 months before switching to less hazardous antiplatelet regimens.

G.J.H. was an investigator in the MATCH trial, and G.J.H and J.W.E have received honoraria from Boehringer-Ingelheim, Sanofi-Synthelabo, and Bristol-Myers Squibb for lecturing at sponsored scientific symposia.

Received August 26, 2004. Accepted in final form December 1, 2004.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.